Coleusin factor, a novel anticancer diterpenoid, inhibits osteosarcoma growth by inducing bone morphogenetic protein-2-dependent differentiation

Molecular Cancer Therapeutics

Volumn 13, Issue 6, 2014, Pages 1431-1441

  Geng, Shuo ^a,b,d   Sun, Bo ^a,b   Lu, Ran ^c   Wang, Jingze ^a  

^a INSTITUTE OF ZOOLOGY   (China)

^b UNIVERSITY OF CHINESE ACADEMY OF SCIENCES   (China)

^c CAPITAL NORMAL UNIVERSITY   (China)

^d VIRGINIA POLYTECHNIC INSTITUTE AND STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; BONE MORPHOGENETIC PROTEIN 2; COLEUSIN FACTOR; DITERPENOID; TRANSCRIPTION FACTOR RUNX2; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; BMP2 PROTEIN, HUMAN; DITERPENE; RUNX2 PROTEIN, HUMAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER GROWTH; CELL CYCLE ARREST; CELL DIFFERENTIATION; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; GROWTH INHIBITION; HUMAN; HUMAN CELL; MINERALIZATION; MOUSE; NONHUMAN; NUDE MOUSE; OSTEOBLAST; OSTEOSARCOMA; OSTEOSARCOMA CELL; PRIORITY JOURNAL; PROTEIN INDUCTION; UPREGULATION; ANIMAL; BIOSYNTHESIS; DRUG EFFECTS; DRUG SCREENING; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; BONE MORPHOGENETIC PROTEIN 2; CELL DIFFERENTIATION; CELL LINE, TUMOR; CORE BINDING FACTOR ALPHA 1 SUBUNIT; DITERPENES; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICE; OSTEOSARCOMA; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84902653805     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-13-0934     Document Type: Article

References (50)

1. Dorfman HD, Czerniak B. Bone cancers. Cancer 1995;75:203-10.
2. Helman LJ, Meltzer P. Mechanisms of sarcoma development. Nat Rev Cancer 2003;3:685-94. (Pubitemid 37328823)
3. Wang LL. Biology of osteogenic sarcoma. Cancer J 2005;11:294-305. (Pubitemid 44698796)
4. Hopyan S, Gokgoz N, Bell RS, Andrulis IL, Alman BA, Wunder JS. Expression of osteocalcin and its transcriptional regulators core- binding factor alpha 1 and MSX2 in osteoid-forming tumors. J Orthop Res 1999;17:633-38.
5. Thomas D, Kansara M. Epigenetic modifications in osteogenic differentiation and transformation. J Cell Biochem 2006;98:757-69. (Pubitemid 43993394)
6. Haydon RC, Luu HH, He TC. Osteosarcoma and osteoblastic differentiation: a new perspective on oncogenesis. Clin Orthop Relat Res 2007;454:237-46. (Pubitemid 46066041)
7. Tang N, Song WX, Luo J, Haydon RC, He TC. Osteosarcoma development and stem cell differentiation. Clin Orthop Relat Res 2008;466: 2114-30.
8. Damron TA, Ward WG, Stewart A. Osteosarcoma, chondrosarcoma, and Ewing's sarcoma: National Cancer Data Base Report. Clin Orthop Relat Res 2007;459:40-47. (Pubitemid 46878192)
9. Haydon RC, Zhou L, Feng T, Breyer B, Cheng H, Jiang W, et al. Nuclear receptor agonists as potential differentiation therapy agents for human osteosarcoma. Clin Cancer Res 2002;8:1288-94. (Pubitemid 34517670)
10. Chou AJ, Gorlick R. Chemotherapy resistance in osteosarcoma: current challenges and future directions. Expert Rev Anticancer Ther 2006;6:1075- 85.
11. Clark JC, Dass CR, Choong PF. A review of clinical and molecular prognostic factors in osteosarcoma. J Cancer Res Clin Oncol 2008; 134:281-97. (Pubitemid 351170066)
12. Wozney JM, Rosen V, Celeste AJ, Mitsock LM, Whitters MJ, Kriz RW, et al. Novel regulators of bone formation: molecular clones and activities. Science 1988;242:1528-34. (Pubitemid 19023695)
13. Ye L, Mason MD, Jiang WG. Bone morphogenetic protein and bone metastasis, implication and therapeutic potential. Front Biosci 2011; 16:865-97.
14. Chen G, Deng C, Li YP. TGF-b and BMP signaling in osteoblast differentiation and bone formation. Int J Biol Sci 2012;8:272-88.
15. Rosen V. BMP2 signaling in bone development and repair. Cytokine Growth Factor Rev 2009;20:475-80.
16. Bais MV, Wigner N, Young M, Toholka R, Graves DT, Morgan EF, et al. BMP2 is essential for post natal osteogenesis but not for recruitment of osteogenic stem cells. Bone 2009;45:254-66.
17. Zhao M, Ko SY, Liu JH, Chen D, Zhang J, Wang B, et al. Inhibition of microtubule assembly in osteoblasts stimulates bone morphogenetic protein 2 expression and bone formation through transcription factor Gli2. Mol Cell Biol 2009;29:1291- 1305.
18. Tsuji K, Bandyopadhyay A, Harfe BD, Cox K, Kakar S, Gerstenfeld L, et al. BMP2 activity, although dispensable for bone formation, is required for the initiation of fracture healing. Nat Genet 2006;38: 1424-29. (Pubitemid 44837565)
19. Katagiri T, Yamaguchi A, Komaki M, Abe E, Takahashi N, Ikeda T, et al. Bone morphogenetic protein-2 converts the differentiation pathway of C2C12 myoblasts into the osteoblast lineage. J Cell Biol 1994;127: 1755-66. (Pubitemid 24380911)
20. Chalaux E, López-Rovira T, Rosa JL, Bartrons R, Ventura F. JunB is involved in the inhibition of myogenic differentiation by bone morphogenetic protein-2. J Biol Chem 1998;273:1537-43.
21. Huang W, Rudkin GH, Carlsen B, Ishida K, Ghasri P, Anvar B, et al. Overexpression of BMP -2 modulates morphology, growth, and gene expression in osteoblastic cells. Exp Cell Res 2002;274:226-34.
22. Jian Y, Jingze W. CF mediated G1 arrest is associated with induction of p27(Kip1) and inhibition of cyclin D1 expression in human hepatoma HepG2 cells. Hepatol Res 2006;35:88-95.
23. Sun B, Geng S, Huang X, Zhu J, Liu S, Zhang Y, et al. Coleusin factor exerts cytotoxic activity by inducing G0/G1 cell cycle arrest and apoptosis in human gastric cancer BGC-823 cells. Cancer Lett 2011; 301:95-105.
24. Geng S, Sun B, Liu S, Wang J. Up-regulation of connexin 43 and gap junctional intercellular communication by Coleusin Factor is associated with growth inhibition in rat osteosarcoma UMR106 cells. Cell Biol Int 2007;31:1420-27. (Pubitemid 47361881)
25. Lee CH, Huang YL, Liao JF, Chiou WF. Ugonin K promotes osteoblastic differentiation and mineralization by activation of p38 MAPKand ERK-mediated expression of Runx2 and osterix. Eur J Pharmacol 2011;668:383-89.
26. Diamantino TC, Almeida E, Soares AM, Guilhermino L. Lactate dehydrogenase activity as an effect criterion in toxicity tests with Daphnia magna straus. Chemosphere 2001;45:553-60. (Pubitemid 32923527)
27. Yan F, Wang M, Chen H, Su J, Wang X, Wang F, et al. Gambogenic acid mediated apoptosis through the mitochondrial oxidative stress and inactivation of Akt signaling pathway in human nasopharyngeal carcinoma CNE-1 cells. Eur J Pharmacol 2011;652:23-32.
28. Mirabello L, Troisi RJ, Savage SA. Osteosarcoma incidence and survival rates from 1973 to 2004: data from the Surveillance, Epidemiology, and End Results Program. Cancer 2009;115:1531-43.
29. Mintz MB, Sowers R, Brown KM, Hilmer SC, Mazza B, Huvos AG, et al. An expression signature classifies chemotherapy-resistant pediatric osteosarcoma. Cancer Res 2005;65:1748-54. (Pubitemid 40478600)
30. Endo-Munoz L, Cumming A, Sommerville S, Dickinson I, Saunders NA. Osteosarcoma is characterised by reduced expression of markers of osteoclastogenesis and antigen presentation compared with normal bone. Br J Cancer 2010;103:73-81.
31. Janeway KA, Grier HE. Sequelae of osteosarcoma medical therapy: a review of rare acute toxicities and late effects. Lancet Oncol 2010; 11:670-78.
32. Ren J, Hamada J, Okada F, Takeichi N, Morikawa K, Hosokawa M, et al. Correlation between the presence of microvilli and the growth or metastatic potential of tumor cells. Jpn J Cancer Res 1990;81:920-26. (Pubitemid 20283761)
33. Wagner ER, Luther G, Zhu G, Luo Q, Shi Q, Kim SH, et al. Defective osteogenic differentiation in the development of osteosarcoma. Sarcoma 2011;2011:325238.
34. Wennberg C, Hessle L, Lundberg P, Mauro S, Narisawa S, Lerner UH, et al. Functional characterization of osteoblasts and osteoclasts from alkaline phosphatase knockout mice. J Bone Miner Res 2000;15: 1879-88.
35. Gordon JA, Tye CE, Sampaio AV, Underhill TM, Hunter GK, Goldberg HA. Bone sialoprotein expression enhances osteoblast differentiation and matrix mineralization in vitro. Bone 2007;41:462-73. (Pubitemid 47199144)
36. Mizuno M, Fujisawa R, Kuboki Y. Type I collagen-induced osteoblastic differentiation of bone-marrow cells mediated by collagen-alpha2-beta1 integrin interaction. J Cell Physiol 2000;184:207-13. (Pubitemid 30432312)
37. Higuchi C, Myoui A, Hashimoto N, Kuriyama K, Yoshioka K, Yoshikawa H, et al. Continuous inhibition of MAPK signaling promotes the early osteoblastic differentiation and mineralization of the extracellular matrix. J Bone Miner Res 2002;17:1785-94.
38. Shi SL, Li QF, Liu QR, Xu DH, Tang J, Liang Y, et al. Nuclear matrix protein, prohibitin, was down-regulated and translocated from nucleus to cytoplasm during the differentiation of osteosarcoma MG-63 cells induced by ginsenoside Rg1, cinnamic acid, and tanshinone IIA (RCT). J Cell Biochem 2009;108:926-34.
39. Cain JE, McCaw A, Jayasekara WS, Rossello FJ, Marini KD, Irving AT, et al. Sustained low-dose treatment with the histone deacetylase inhibitor LBH589 induces terminal differentiation of osteosarcoma cells. Sarcoma 2013;2013:608964.
40. Salvatori L, Caporuscio F, Coroniti G, Starace G, Frati L, Russo MA, et al. Down-regulation of epidermal growth factor receptor induced by estrogens and phytoestrogens promotes the differentiation of U2OS human osteosarcoma cells. J Cell Physiol 2009;220:35-44.
41. Luo P, Yang X, Ying M, Chaudhry P, Wang A, Shimada H, et al. Retinoid-suppressed phosphorylation of RARalpha mediates the differentiation pathway of osteosarcoma cells. Oncogene 2010;29: 2772-83.
42. He BC, Chen L, Zuo GW, Zhang W, Bi Y, Huang J, et al. Synergistic antitumor effect of the activated PPARgamma and retinoid receptors on human osteosarcoma. Clin Cancer Res 2010;16:2235-45.
43. Heldin CH, Miyazono K, ten Dijke P. TGF-beta signalling from cell membrane to nucleus through SMAD proteins. Nature 1997;390: 465-71. (Pubitemid 28013118)
44. Ducy P, Zhang R, Geoffroy V, Ridall AL, Karsenty G. Osf2/Cbfa1: a transcriptional activator of osteoblast differentiation. Cell 1997;89: 747-54. (Pubitemid 27516177)
45. Komori T, Yagi H, Nomura S, Yamaguchi A, Sasaki K, Deguchi K, et al. Targeted disruption of Cbfa1 results in a complete lack of bone formation owing to maturational arrest of osteoblasts. Cell 1997; 89:755-64. (Pubitemid 27516178)
46. Thomas DM, Johnson SA, Sims NA, Trivett MK, Slavin JL, Rubin BP, et al. Terminal osteoblast differentiation, mediated by runx2 and p27KIP1, is disrupted in osteosarcoma. J Cell Biol 2004;167: 925-34. (Pubitemid 39628114)
47. Kawamura C, Kizaki M, Yamato K, Uchida H, Fukuchi Y, Hattori Y, et al. Bone morphogenetic protein -2 induces apoptosis in human myeloma cells with modulation of STAT3. Blood 2000;96:2005-11.
48. Ide H, Yoshida T, Matsumoto N, Aoki K, Osada Y, Sugimura T, et al. Growth regulation of human prostate cancer cells by bone morphogenetic protein-2. Cancer Res 1997;57:5022-27. (Pubitemid 27498113)
49. Ghosh-Choudhury N, Ghosh-Choudhury G, Celeste A, Ghosh PM, Moyer M, Abboud SL, et al. Bone morphogenetic protein-2 induces cyclin kinase inhibitor p21 and hypophosphorylation of retinoblastoma protein in estradiol-treated MCF-7 human breast cancer cells. Biochim Biophys Acta 2000;1497:186-96.
50. Wang L, Park P, Zhang H, La Marca F, Claeson A, Than K, et al. BMP-2 inhibits tumor growth of human renal cell carcinoma and induces bone formation. Int J Cancer 2012;131:1941-50.